Microbial Biotechnology laboratory, Department of Zoology, University of Azad Jammu and Kashmir, Muzaffarabad, 13100, Pakistan.
Department of Zoology, Government College University, Lahore, Pakistan.
Curr Pharm Biotechnol. 2022;23(3):318-336. doi: 10.2174/1389201022666210421101837.
Ajuga bracteosa is a traditional herb used against various diseases.
Current research aimed to investigate the anti-diabetic and hepato-protective effect of green synthesized silver nanoparticles (ABAgNPs) using Ajuga bracteosa aqueous extract (ABaqu).
In vitro anti-diabetic and cytotoxic effects were carried out via α- glucosidase inhibition, brine shrimp lethality, and protein kinase inhibition assays. For in vivo screening of 200 mg/kg and 400 mg/kg of both ABAgNPs and ABaqu in alloxan-induced and CCl4-induced Swiss albino mice were used. Liver and kidney functional markers, hematology, and histopathological studies were carried out after 14 days of administration.
In vivo antidiabetic and anti-cancerous effects showed valuable anti-hyperglycemic and hepatoprotective potential when mice were treated with ABaqu and ABAgNPs. A significant reduction in the blood glucose level was recorded when ABaqu and ABAgNPs were administrated orally compared to Glibenclamide treated group. Significant reduction in ALT, AST, ALP, urea, uric acid, and creatinine was recorded in ABaqu and ABAgNPs treated diabetic mice. The hepato-protective findings indicated that ALT, ALP, AST were elevated in CCl4-induced mice while declined in both ABAgNPs and ABaqu treated CCl4-induced mice. Histopathological examination revealed that ABAgNPs have hepato-protective activity.
It was concluded that ABAgNPs and ABaqu possessed strong anti-diabetic and hepatoprotective phytoconstituents, which could be used in the prevention of diseases.
筋骨草是一种传统草药,用于治疗多种疾病。
本研究旨在利用筋骨草水提物(ABaqu)来研究绿色合成的银纳米粒子(ABAgNPs)的抗糖尿病和保肝作用。
通过α-葡萄糖苷酶抑制、卤虫致死和蛋白激酶抑制试验进行体外抗糖尿病和细胞毒性作用研究。采用 200mg/kg 和 400mg/kg 的 ABAgNPs 和 ABaqu 对四氧嘧啶和 CCl4 诱导的瑞士白化病小鼠进行体内筛选。给药 14 天后,进行肝功能和肾功能标志物、血液学和组织病理学研究。
体内抗糖尿病和抗癌作用研究表明,ABaqu 和 ABAgNPs 对糖尿病小鼠具有显著的降血糖和保肝作用。与格列本脲治疗组相比,ABaqu 和 ABAgNPs 口服给药可显著降低血糖水平。ABaqu 和 ABAgNPs 治疗的糖尿病小鼠的 ALT、AST、ALP、尿素、尿酸和肌酐水平显著降低。肝保护作用研究表明,CCl4 诱导的小鼠的 ALT、ALP 和 AST 升高,而 ABAgNPs 和 ABaqu 治疗的 CCl4 诱导的小鼠的 ALT、ALP 和 AST 降低。组织病理学检查显示 ABAgNPs 具有保肝活性。
ABAgNPs 和 ABaqu 具有较强的抗糖尿病和保肝植物成分,可用于预防疾病。